Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
NCT00407797
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Male or Female who are diagnosed of partial seizure (simple partial, complex partial, partial seizure secondarily generalized) as defined in the international league of epilepsy classification of seizure.
- Patients having a treatable cause of seizure, currently receiving vigabatrin, having a
progressive neurological or systemic disorder.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mexico, D. F.
- Acapulco, Guerrero
- Morelia, Michoacan
- Monterrey,, Nuevo Leon
- Monterrey, Nuevo Leon
- Aguascalientes,
- Chihuahua,
- Estado de México,
- Daegu,
- Daejeon,
- Gwangju,
- Incheon,
- Seoul,
- Duffel,
- Yvoir,
- Kyustendil 2500,
- Pernik,
- Plovdiv,
- Ruse 7002,
- Sofia,
- Sofia,
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Montes de Oca, San Jose
- San Jose,
- Brno 2,
- Brno,
- Hradec Kralove 3,
- Olomouc,
- Ostrava-Trebovice,
- Praha 4,
- Pribram 8,
- Rychnov nad Kneznou,
- Strasbourg Cedex,
- Toulouse,
- Bonn,
- Hamburg,
- Athens,
- Thessaloniki,
- Pune, Maharashtra
- Chandigarh, Punjab
- Ludhiana, Punjab
- Firenze,
- Foggia,
- Pisa,
- Siena,
- Busan,
- Daejeon,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Kaunas,
- Vilnius,
- Distrito Federal,
- San Luis Potosi,
- Panama,
- Lima,
- Lima,
- Tondo, Manila
- Cebu City,
- Davao City,
- Makati City,
- Manila,
- Quezon City,
- Moscow,
- Moscow,
- Moscow,
- St. Petersburg,
- St. Petersburg,
- St. Petersburg,
- Donostia, Guipuzcoa
- Alicante,
- Barcelona,
- Cordoba,
- Girona,
- Sevilla,
- Kaohsiung,
- Taichung,
- Tainan,
- Capa, Istanbul
- Ankara,
- Cerrahpasa / Istanbul,
- Caracas, Libertador
- Caracas, Miranda
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial | |||
Official Title ICMJE | Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin | |||
Brief Summary | The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration, BID) to existing standard AED (Antiepileptic drugs). | |||
Detailed Description | This study was terminated on 17 March 2009 due to delayed enrollment. The decision to terminate the trial was not based on any safety concerns, but rather on timelines and the difficulty in enrolling patients in this open label, single group study. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Partial Seizures | |||
Intervention ICMJE | Drug: Pregabalin
150 to 600 mg/day during 21 weeks | |||
Study Arms ICMJE | Experimental: Pregabalin
Intervention: Drug: Pregabalin | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 136 | |||
Original Enrollment ICMJE | 160 | |||
Actual Study Completion Date ICMJE | August 2009 | |||
Actual Primary Completion Date | August 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Mexico | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00407797 | |||
Other Study ID Numbers ICMJE | A0081090 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trials Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | February 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |